What is the current Price Target for the Arrivent Biopharma Inc stock?

The average Arrivent Biopharma Inc target price is $45.90. This is 62.36% higher than the current stock price. The highest price target is 85.71%, the lowest is 42.91%. 13 Analysts have issued a price target Arrivent Biopharma Inc 2027 .

How high will the Arrivent Biopharma Inc stock rise?

No reliable answer can be given as to how high the Arrivent Biopharma Inc stock will rise. The performance of stocks, including the Arrivent Biopharma Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Arrivent Biopharma Inc stock today?

The performance of Arrivent Biopharma Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Arrivent Biopharma Inc stock fall?

The decline in Arrivent Biopharma Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Arrivent Biopharma Inc Forecast, price target & analysts

$28.27

2.28%

Nasdaq, Oct 02, 04:00 pm EDT. Closed.

ISIN

US04272N1028

Symbol

AVBP

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Arrivent Biopharma Inc Target price 2026 - Analyst rating & recommendation

Arrivent Biopharma Inc Classifications & Recommendation

Buy

94%

Hold

Arrivent Biopharma Inc Price Target

Target Price	$45.90
Price	$28.27
Potential	62.36% register free of charge
Number of Estimates	13

	13 Analysts have issued a price target Arrivent Biopharma Inc 2027 . The average Arrivent Biopharma Inc target price is $45.90. This is 62.36% register free of charge higher than the current stock price. The highest price target is $52.50 85.71% register free of charge , the lowest is $40.40 42.91% register free of charge .
	A rating was issued by 18 analysts: 17 Analysts recommend Arrivent Biopharma Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Arrivent Biopharma Inc stock has an average upside potential 2027 of 62.36% register free of charge . Most analysts recommend the Arrivent Biopharma Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-4.32	-4.38
	68.75%	1.39%
P/E		negative

14 Analysts have issued a Arrivent Biopharma Inc forecast for earnings per share. The average Arrivent Biopharma Inc EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-4.32	68.75%
2026	$-4.38 1.39% unlock
2027	$-3.98 9.13% unlock
2028	$-1.88 52.76% unlock
2029	$1.85 198.40% unlock
2030	$4.80 159.46% unlock
2031	$7.98 66.25% unlock
2032	$10.75 34.71% unlock
2033	$13.04 21.30% unlock

Current	-8.24	78.73%
2026	-6.46 21.62% unlock
2027	-7.10 9.91% unlock
2028	-15.08 112.39% unlock
2029	15.29 201.39% unlock
2030	5.89 61.48% unlock
2031	3.54 39.90% unlock
2032	2.63 25.71% unlock
2033	2.17 17.49% unlock

Arrivent Biopharma Inc...

Current Arrivent Biopharma Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 17 2026
BTIG	Locked ➜ Locked	Locked	Aug 13 2026
Citigroup	Locked ➜ Locked	Locked	Aug 13 2026
Guggenheim	Locked ➜ Locked	Locked	Aug 13 2026
Truist Securities	Locked ➜ Locked	Locked	May 29 2026
Citigroup	Locked ➜ Locked	Locked	May 13 2026
Citigroup	Locked ➜ Locked	Locked	Apr 24 2026

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 17 2026
Locked BTIG: Locked ➜ Locked	Aug 13 2026
Locked Citigroup: Locked ➜ Locked	Aug 13 2026
Locked Guggenheim: Locked ➜ Locked	Aug 13 2026
Locked Truist Securities: Locked ➜ Locked	May 29 2026
Locked Citigroup: Locked ➜ Locked	May 13 2026
Locked Citigroup: Locked ➜ Locked	Apr 24 2026

Discover more stocks with a high price target

NIO ADR 86.90%

Alibaba Group Holding Ltd 81.89%

Rheinmetall 70.55%

Tencent Holdings Ltd. 61.28%

Adyen 56.67%

Uber Technologies 51.26%

BYD 50.30%

Siemens Energy 43.79%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now